BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 16123561)

  • 1. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers.
    Koksal IT; Yasar D; Dirice E; Usta MF; Karauzum S; Luleci G; Baykara M; Sanlioglu S
    Urol Int; 2005; 75(2):102-6. PubMed ID: 16123561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors.
    Lee JS; Leem SH; Lee SY; Kim SC; Park ES; Kim SB; Kim SK; Kim YJ; Kim WJ; Chu IS
    J Clin Oncol; 2010 Jun; 28(16):2660-7. PubMed ID: 20421545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.
    Tsuruta H; Kishimoto H; Sasaki T; Horie Y; Natsui M; Shibata Y; Hamada K; Yajima N; Kawahara K; Sasaki M; Tsuchiya N; Enomoto K; Mak TW; Nakano T; Habuchi T; Suzuki A
    Cancer Res; 2006 Sep; 66(17):8389-96. PubMed ID: 16951148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of p53 nuclear overexpression in patients of muscle invasive urinary bladder carcinoma treated with cystectomy.
    Hemal AK; Khaitan A; Dinda AK; Gupta NP; Seth A; Dogra PN; Nabi G
    Urol Int; 2003; 70(1):42-6. PubMed ID: 12566814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
    Kunze E; Wendt M; Schlott T
    Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD; Sosa RE; Vaughan ED; Scherr DS
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 expression predicts progression and poor survival in T1 bladder tumours.
    Llopis J; Alcaraz A; Ribal MJ; Solé M; Ventura PJ; Barranco MA; Rodriguez A; Corral JM; Carretero P
    Eur Urol; 2000 Jun; 37(6):644-53. PubMed ID: 10828662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory).
    Sözen S; Akbal C; Sökmensüer C; Ekici S; Ozen H
    Urol Int; 2002; 69(3):200-6. PubMed ID: 12372888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
    Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
    Novara G; De Marco V; Gottardo F; Dalpiaz O; Bouygues V; Galfano A; Martignoni G; Patard JJ; Artibani W; Ficarra V
    Cancer; 2007 Oct; 110(8):1715-22. PubMed ID: 17724728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
    Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
    Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
    Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
    Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
    Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
    Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
    Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
    J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-phase fraction in superficial urothelial carcinoma of the bladder--a prospective, long-term, follow-up study.
    Falkman K; Tribukait B; Nyman CR; Larsson P; Norming U
    Scand J Urol Nephrol; 2004; 38(4):278-84. PubMed ID: 15669586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.